Liquidia Corp (LQDA) stock
LQDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/3075% above fair value
$56.73+0.36 (+0.64%)
Close on Nov 17, 2026Market cap $5.08BP/E 40.8Yield –
Liquidia r&d expenses
Research and development expenses are spending on new products and technology.
Liquidia's R&D Expenses for the twelve months ending Jun 30, 2026 was $56.04M, up 35.5% year over year. For fiscal 2025 it was $39.28M, down 17.9% from the year before. The highest annual figure on record is $47.84M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.28M | -17.9% |
| FY2024 | Dec 31, 2024 | $47.84M | +10.6% |
| FY2023 | Dec 31, 2023 | $43.24M | +122.5% |
| FY2022 | Dec 31, 2022 | $19.44M | -5.3% |
| FY2021 | Dec 31, 2021 | $20.52M | -36.3% |
| FY2020 | Dec 31, 2020 | $32.22M | -20.4% |
| FY2019 | Dec 31, 2019 | $40.49M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $17.18M | +185.4% |
| Q1 FY2026 | Mar 31, 2026 | $12.57M | +80.5% |
| Q4 FY2025 | Dec 31, 2025 | $16.94M | +2.8% |
| Q3 FY2025 | Sep 30, 2025 | $9.35M | -21.4% |
| Q2 FY2025 | Jun 30, 2025 | $6.02M | -36.1% |
| Q1 FY2025 | Mar 31, 2025 | $6.97M | -30.7% |
| Q4 FY2024 | Dec 31, 2024 | $16.48M | +28.4% |
| Q3 FY2024 | Sep 30, 2024 | $11.89M | +59.8% |
| Q2 FY2024 | Jun 30, 2024 | $9.42M | -46.8% |
| Q1 FY2024 | Mar 31, 2024 | $10.06M | +90.5% |
| Q4 FY2023 | Dec 31, 2023 | $12.83M | +157.8% |
| Q3 FY2023 | Sep 30, 2023 | $7.44M | +64.9% |
| Q2 FY2023 | Jun 30, 2023 | $17.70M | +239.0% |
| Q1 FY2023 | Mar 31, 2023 | $5.28M | +11.6% |
| Q4 FY2022 | Dec 31, 2022 | $4.98M | -7.5% |
| Q3 FY2022 | Sep 30, 2022 | $4.51M | +0.6% |
| Q2 FY2022 | Jun 30, 2022 | $5.22M | +13.6% |
| Q1 FY2022 | Mar 31, 2022 | $4.73M | -21.9% |
| Q4 FY2021 | Dec 31, 2021 | $5.38M | +2.5% |
| Q3 FY2021 | Sep 30, 2021 | $4.49M | -41.4% |
| Q2 FY2021 | Jun 30, 2021 | $4.60M | -45.9% |
| Q1 FY2021 | Mar 31, 2021 | $6.05M | -44.1% |
| Q4 FY2020 | Dec 31, 2020 | $5.25M | – |
| Q3 FY2020 | Sep 30, 2020 | $7.66M | – |
| Q2 FY2020 | Jun 30, 2020 | $8.49M | – |
| Q1 FY2020 | Mar 31, 2020 | $10.82M | – |
See a number that looks wrong?